Testosterone in males with COVID-19: a 12-month cohort study.

Autor: Salonia A; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy., Pontillo M; Laboratory Medicine Service, IRCCS Ospedale San Raffaele, Milan, Italy., Capogrosso P; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.; Department of Urology and Andrology, Ospedale di Circolo and Macchi Foundation, Varese, Italy., Pozzi E; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy., Ferrara AM; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy., Cotelessa A; Laboratory Medicine Service, IRCCS Ospedale San Raffaele, Milan, Italy., Belladelli F; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy., Corsini C; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy., Gregori S; San Raffaele Telethon Institute for Gene Therapy (SR-TIGET), IRCCS Ospedale San Raffaele, Milan, Italy., Rowe I; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy., Carenzi C; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy., Ramirez GA; University Vita-Salute San Raffaele, Milan, Italy.; Immunology, Rheumatology, Allergology and Rare Diseases Unit, IRCCS Ospedale San Raffaele, Milan, Italy., Tresoldi C; Molecular Hematology Unit, IRCCS Ospedale San Raffaele, Milan, Italy., Locatelli M; Laboratory Medicine Service, IRCCS Ospedale San Raffaele, Milan, Italy., Cavalli G; University Vita-Salute San Raffaele, Milan, Italy.; Immunology, Rheumatology, Allergology and Rare Diseases Unit, IRCCS Ospedale San Raffaele, Milan, Italy., Dagna L; University Vita-Salute San Raffaele, Milan, Italy.; Immunology, Rheumatology, Allergology and Rare Diseases Unit, IRCCS Ospedale San Raffaele, Milan, Italy., Castagna A; University Vita-Salute San Raffaele, Milan, Italy.; Department of Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy., Zangrillo A; University Vita-Salute San Raffaele, Milan, Italy.; Anesthesia and Intensive Care Department, IRCCS Ospedale San Raffaele, Milan, Italy., Tresoldi M; General Medicine and Advanced Care Unit, IRCCS Ospedale San Raffaele, Milan, Italy., Landoni G; University Vita-Salute San Raffaele, Milan, Italy.; Anesthesia and Intensive Care Department, IRCCS Ospedale San Raffaele, Milan, Italy., Rovere-Querini P; University Vita-Salute San Raffaele, Milan, Italy.; Internal Medicine, Diabetes, and Endocrinology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy., Ciceri F; University Vita-Salute San Raffaele, Milan, Italy.; Hematology and Bone Marrow Transplant Unit, IRCCS Ospedale San Raffaele, Milan, Italy., Montorsi F; Division of Experimental Oncology/Unit of Urology, URI; IRCCS Ospedale San Raffaele, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy.
Jazyk: angličtina
Zdroj: Andrology [Andrology] 2023 Jan; Vol. 11 (1), pp. 17-23. Date of Electronic Publication: 2022 Oct 27.
DOI: 10.1111/andr.13322
Abstrakt: Background: Male patients with COVID-19 have been found with reduced serum total testosterone (tT) levels and with more severe clinical outcomes.
Objectives: To assess total testosterone (tT) levels and the probability of recovering eugonadal tT levels during a minimum 12-month timespan in a cohort of men who have been followed over time after the recovery from laboratory-confirmed COVID-19.
Materials and Methods: Demographic, clinical and hormonal values were collected for the overall cohort. Hypogonadism was defined as tT ≤9.2 nmol/l. The Charlson Comorbidity Index was used to score health-significant comorbidities. Descriptive statistics was used to compare hormonal levels at baseline versus 7-month (FU1) versus 12-month (FU2) follow-up, respectively. Multivariate cox proportional hazards regression model was used to identify the potential predictors of eugonadism recovery over time among patients with hypogonadism at the time of infection.
Results: Of the original cohort of 286 patients, follow-up data were available for 121 (42.3%) at FU1 and 63 (22%) patients at FU2, respectively. Higher median interquartile range (IQR) tT levels were detected at FU2 (13.8 (12.3-15.3) nmol/L) versus FU1 (10.2 [9.3-10.9] nmol/L) and versus baseline (3.6 [3.02-4.02] nmol/L) (all p < 0.0001), whilst both LH and E 2 levels significantly decreased over the same time frame (all p ≤ 0.01). Circulating IL-6 levels further decreased at FU2 compared to FU1 levels (19.3 vs. 72.8 pg/ml) (p = 0.02). At multivariable cox regression analyses, baseline tT level (HR 1.19; p = 0.03 [1.02-1.4]) was independently associated with the probability of tT level normalization over time, after adjusting for potential confounders.
Conclusions: Circulating tT levels keep increasing over time in men after COVID-19. Still, almost 30% of men who recovered from COVID-19 had low circulating T levels suggestive for a condition of hypogonadism at a minimum 12-month follow-up.
(© 2022 American Society of Andrology and European Academy of Andrology.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje